{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:32:39Z","timestamp":1783524759485,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,14]],"date-time":"2027-01-14T00:00:00Z","timestamp":1799884800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["T90-DE02198213"],"award-info":[{"award-number":["T90-DE02198213"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["00430A121"],"award-info":[{"award-number":["00430A121"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BERING21A0"],"award-info":[{"award-number":["BERING21A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:23:10Z","timestamp":1758068590000},"page":"151-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the drug interaction between rifabutin and elexacaftor\/tezacaftor\/ivacaftor (ETI)"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8386-0907","authenticated-orcid":false,"given":"Madeline","family":"Sanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6696-3948","authenticated-orcid":false,"given":"Eunjin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-2119","authenticated-orcid":false,"given":"Peter S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0220-7131","authenticated-orcid":false,"given":"Adupa P.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9198-8904","authenticated-orcid":false,"given":"Whitaker","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-3310","authenticated-orcid":false,"given":"Paul","family":"Beringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jcf.2025.09.002_bib0001","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.002_bib0002","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010\u20132014","volume":"15","author":"Adjemian","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.002_bib0004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12879-023-08468-6","article-title":"Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010\u20132019)","volume":"23","author":"Marshall","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.jcf.2025.09.002_bib0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ccm.2023.06.008","article-title":"Cystic fibrosis-related nontuberculous mycobacterial pulmonary disease","volume":"44","author":"Baird","year":"2023","journal-title":"Clin Chest Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.002_bib0006","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1513\/AnnalsATS.201309-310OC","article-title":"Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis","volume":"11","author":"Martiniano","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.01.071","article-title":"CFTR protects against Mycobacterium abscessus infection by fine-tuning host oxidative defenses","volume":"26","author":"Bernut","year":"2019","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.002_bib0008","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1164\/rccm.200207-678OC","article-title":"Nontuberculous mycobacteria in cystic fibrosis study group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis","volume":"167","author":"Olivier","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.09.002_bib0009","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3201\/eid1403.061405","article-title":"Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel","volume":"14","author":"Levy","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.jcf.2025.09.002_bib0010","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01257-09","article-title":"Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France","volume":"47","author":"Roux","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.002_bib0011","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3201\/eid1907.120615","article-title":"Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009","volume":"19","author":"Seddon","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.002_bib0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcf.2014.08.002","article-title":"Scandinavian Cystic Fibrosis Study Consortium (SCFSC). Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia","volume":"14","author":"Qvist","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"10212","key":"10.1016\/j.jcf.2025.09.002_bib0013","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jcf.2025.09.002_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"PROMISE Study Group. Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.09.002_bib0016","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2025.09.002_bib0017","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1128\/AAC.06282-11","article-title":"Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects","volume":"56","author":"Vourvahis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jcf.2025.09.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223969","article-title":"A drug interaction study investigating the effect of rifabutin on the pharmacokinetics of maraviroc in healthy subjects","volume":"14","author":"Ghannad","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2025.09.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1103","article-title":"Multiple doses of rifabutin reduce exposure of doravirine in healthy subjects","author":"Khalilieh","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jcf.2025.09.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01104-22","article-title":"Physiologically based pharmacokinetic modeling to guide management of drug interactions between elexacaftor-tezacaftor-ivacaftor and antibiotics for the treatment of nontuberculous mycobacteria","volume":"66","author":"Hong","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2025.09.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jcf.2025.09.002_bib0022","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Multi-Discipline Review, elexacaftor\/tezacaftor\/ivacaftor. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf."},{"key":"10.1016\/j.jcf.2025.09.002_bib0023","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s), tezacaftor\/ivacaftor. 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000ClinPharmR.pdf."},{"issue":"2","key":"10.1016\/j.jcf.2025.09.002_bib0024","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor\/tezacaftor\/ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jcf.2025.09.002_bib0025","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s), ivacaftor. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188Orig1s000ClinPharmR.pdf."},{"issue":"1","key":"10.1016\/j.jcf.2025.09.002_bib0026","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00204-023-03618-w","article-title":"Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site","volume":"98","author":"Phondeth","year":"2024","journal-title":"Arch Toxicol"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.002_bib0027","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s13318-022-00791-8","article-title":"Phase 1 study to assess the safety and pharmacokinetics of elexacaftor\/tezacaftor\/ivacaftor in subjects without cystic fibrosis with moderate hepatic impairment","volume":"47","author":"Viswanathan","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jcf.2025.09.002_bib0028","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jcf.2023.11.015","article-title":"Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration","volume":"23","author":"Hong","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2025.2458341","article-title":"The complexities of elexacaftor\/tezacaftor\/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease","volume":"12","author":"Mou","year":"2025","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.jcf.2025.09.002_bib0030","unstructured":"Pharmacia and Upjohn Co. Mycobutin (rifabutin) package insert. U.S. Food and Drug Administration. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050689s016lbl.pdf."},{"issue":"9028","key":"10.1016\/j.jcf.2025.09.002_bib0031","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(05)65109-4","article-title":"Severe neutropenia caused by recommended prophylactic doses of rifabutin","volume":"348","author":"Apseloff","year":"1996","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jcf.2025.09.002_bib0032","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/j.1552-4604.1998.tb00017.x","article-title":"Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers","volume":"38","author":"Apseloff","year":"1998","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jcf.2025.09.002_bib0033","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone","volume":"38","author":"LeBel","year":"1998","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2025.09.002_bib0034","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1128\/AAC.45.5.1572-1577.2001","article-title":"DATRI 001B Study Group. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin","volume":"45","author":"Hafner","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jcf.2025.09.002_bib0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1067\/mcp.2003.3","article-title":"AIDS Clinical Trials Group 365 Study Team. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin","volume":"73","author":"Hamzeh","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00855-17","article-title":"Impact of rifabutin or rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers","volume":"62","author":"Healan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9041","key":"10.1016\/j.jcf.2025.09.002_bib0037","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0140-6736(05)66217-4","article-title":"Severe neutropenia and prophylactic doses of rifabutin","volume":"348","author":"Tansey","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jcf.2025.09.002_bib0038","first-page":"1551","article-title":"Pharmacokinetics in patients with cystic fibrosis: a systematic review of data published between 1999 and 2019","volume":"59","author":"Gasthuys","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcf.2025.09.002_bib0039","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"10.1016\/j.jcf.2025.09.002_bib0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in cystic fibrosis: prevalence, trends, and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"23","key":"10.1016\/j.jcf.2025.09.002_bib0041","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2025.09.002_bib0042","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/psp4.13134","article-title":"Development of a cystic fibrosis population model for physiologically based PK models: Is it worth it?","volume":"13","author":"Hong","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"12","key":"10.1016\/j.jcf.2025.09.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082562","article-title":"Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy","volume":"8","author":"Preissner","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.002_bib0044","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1023\/B:PHAM.0000029276.21063.0b","article-title":"Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)","volume":"21","author":"Pauli-Magnus","year":"2004","journal-title":"Pharm Res"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:39Z","timestamp":1778822079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325015814"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.09.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the drug interaction between rifabutin and elexacaftor\/tezacaftor\/ivacaftor (ETI)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}